均瑶健康(605388) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 401,482,952.19, representing a year-over-year increase of 1.41% compared to CNY 395,905,330.07 in the same period last year[4] - Net profit attributable to shareholders decreased by 58.29% to CNY 10,907,104.58 from CNY 26,150,321.80 in the previous year[4] - The net profit after deducting non-recurring gains and losses dropped by 70.46% to CNY 7,029,713.48 from CNY 23,794,077.50 year-over-year[4] - Basic and diluted earnings per share fell by 50.00% to CNY 0.02 from CNY 0.04 in the same period last year[4] - Total operating revenue for Q1 2025 was ¥401,482,952.19, a slight increase of 1.46% compared to ¥395,905,330.07 in Q1 2024[26] - Net profit for Q1 2025 was ¥9,622,479.68, down 62.5% from ¥25,691,096.53 in Q1 2024[27] - The company reported a total profit of ¥13,081,988.48 for Q1 2025, down from ¥34,518,629.33 in Q1 2024, a decline of 62.1%[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,173,223,750.91, a decrease of 6.06% from CNY 2,313,498,343.10 at the end of the previous year[5] - Current assets decreased to CNY 958,327,705.52 from CNY 1,080,864,363.47, primarily due to a reduction in cash and inventory[21] - Total liabilities decreased to CNY 406,847,133.40 from CNY 548,716,746.59, indicating improved financial stability[23] - The company's equity attributable to shareholders increased slightly to CNY 1,775,791,250.52 from CNY 1,772,911,604.62[23] Cash Flow - The company reported a net cash flow from operating activities of CNY -97,063,782.94, an improvement from CNY -129,488,834.36 in the previous year[4] - Cash flow from operating activities showed a net outflow of ¥97,063,782.94 in Q1 2025, an improvement from a net outflow of ¥129,488,834.36 in Q1 2024[29] - Cash and cash equivalents at the end of Q1 2025 were ¥123,633,938.76, down from ¥225,990,046.68 at the end of Q1 2024[30] - Investment activities generated a net cash inflow of ¥4,953,107.36 in Q1 2025, contrasting with a net outflow of ¥78,431,446.71 in Q1 2024[30] Expenses - Total operating costs increased to ¥391,483,113.73 in Q1 2025 from ¥363,845,443.70 in Q1 2024, representing a rise of 7.66%[26] - Research and development expenses increased to ¥10,076,572.33 in Q1 2025 from ¥7,328,907.08 in Q1 2024, reflecting a growth of 37.7%[26] - Sales expenses rose significantly to ¥75,040,972.82 in Q1 2025, compared to ¥42,896,126.63 in Q1 2024, marking an increase of 75.3%[26] Business Development - The decline in net profit was primarily attributed to differences in the sales cycle of probiotic beverages during the Spring Festival compared to the previous year, alongside increased expenses from ongoing investments in new business initiatives[8] - The company reported a strong development momentum in Q1 2025, with traditional beverage business stability and significant growth in the emerging probiotic sector[12] - Probiotic food revenue increased by 139.19% year-on-year in Q1 2025, demonstrating remarkable results[15] - E-commerce channel revenue surged by 1,173.33% year-on-year in Q1 2025, driven by market optimization and enhanced industry collaboration[13] - The company launched innovative probiotic beverages, including daily beauty and sleep aid products, which received multiple innovation awards[14] - The company holds a leading position in the domestic ambient yogurt market, focusing on product innovation and channel development[13] - The company has integrated its probiotic business with Yunnan Runying Biotechnology, enhancing the entire industry chain[15] - The company aims to enhance its market competitiveness through continuous innovation and strategic partnerships in the health industry[17] Shareholder Information - The company has a total of 26,969 shareholders at the end of the reporting period, with the top 10 shareholders holding significant stakes[10] - The company’s repurchase account holds 14,660,000 shares, accounting for 2.44% of the total share capital at the end of the reporting period[11] Research and Development - The subsidiary Junyao Runying has over 30,000 strains in its probiotic resource library, focusing on gut health, weight management, and immune regulation[16] - The company has established partnerships with several universities to enhance its R&D capabilities, resulting in the award-winning strain Lp-G18 and the patented CCFM1166 strain[17] Supply Chain and Operations - The integration of supply chain management and big data has improved operational efficiency, optimizing order processing, inventory management, and logistics[18]